Drugs that contain Varenicline Tartrate
1. Drug name - CHANTIX
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6890927 | PF PRISM CV | Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
May, 2022
(4 months ago) | |
| US7265119 | PF PRISM CV | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Aug, 2022
(a month ago) | |
| CN1509174A | PF PRISM CV | 5, 8, 14-Aminosteroid, Triaza-Tetracyclo [10.3.1.0 |
Apr, 2022
(5 months ago) | |
| CN100370987C | PF PRISM CV | 5, 8, 14-Aminosteroid, Triaza-Tetracyclo [10.3.1.0. 2.11. 0. 4.9]--2 (11), 3, 5, 7, 9, - Pentaene-Tartrate |
Apr, 2022
(5 months ago) | |
| IN200300863P3 | PF PRISM CV | Compound Of 5,8,14-Triazatracyclo[10.3.1.02.11.04.9]-Hexadeca-2(11),3,5,7,9-Pentaene |
Apr, 2022
(5 months ago) | |
| IN204091B | PF PRISM CV | Compound Of 5,8,14-Triazatracyclo[10.3.1.02.11.04.9]-Hexadeca-2(11),3,5,7,9-Pentaene |
Apr, 2022
(5 months ago) | |
| EP1392307B1 | PF PRISM CV | Tartrate Salts Of 5,8,14-Triazatetracyclo¬10.3.1.02,11.04,9-Hexadeca-2(11),3,5,7,9-Pentaene |
Apr, 2022
(5 months ago) | |
| EP1392307A1 | PF PRISM CV | Tartrate Salts Of 5,8,14-Triazatetracyclo[10.3.1.02,11.04,9]-Hexadeca-2(11),3,5,7,9-Pentaene |
Apr, 2022
(5 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6890927
(Pediatric) | PF PRISM CV | Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Nov, 2022
(a month from now) | |
|
US7265119
(Pediatric) | PF PRISM CV | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Feb, 2023
(4 months from now) | |
Treatment: NA
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 0.5MG BASE | TABLET;ORAL | Prescription |
| EQ 1MG BASE | TABLET;ORAL | Prescription |
2. Drug name - TYRVAYA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9504644 | OYSTER POINT PHARMA | Methods of increasing tear production |
Oct, 2035
(13 years from now) | |
| US11224598 | OYSTER POINT PHARMA | Methods of increasing lacrimal proteins |
Oct, 2035
(13 years from now) | |
| US9504645 | OYSTER POINT PHARMA | Pharmaceutical formulations for treating ocular conditions |
Oct, 2035
(13 years from now) | |
| US10456396 | OYSTER POINT PHARMA | Dry eye treatments |
Oct, 2035
(13 years from now) | |
| US9597284 | OYSTER POINT PHARMA | Dry eye treatments |
Oct, 2035
(13 years from now) | |
| US9532944 | OYSTER POINT PHARMA | Methods of improving ocular discomfort |
Oct, 2035
(13 years from now) | |
Treatment: Treatment of the signs and symptoms of dry eye disease (ded)
Dosage: SOLUTION;NASAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 0.03MG BASE/SPRAY | SOLUTION;NASAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.